Template:SubstanceBox/Buprenorphine

From Drugwiki

Jump to: navigation, search
{{#arraydefine: InhaledDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InhaledDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SmokedDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SmokedDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: OralDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: OralDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SublingualDosage | Threshold;<=Sublingual threshold dose::0.3Sublingual dose units::mg, Light;Sublingual min light dose::1 - Sublingual max light dose::2 mg, Common;Sublingual min common dose::2 - Sublingual max common dose::4 mg, Strong;Sublingual min strong dose::4 - Sublingual max strong dose::8 mg, Heavy;Sublingual heavy dose::8mg + }} {{#arraydefine: SublingualDuration | Total;Sublingual min total time::18 - Sublingual max total time::24Sublingual total time units::hours, Onset;Sublingual min onset time::40 - Sublingual max onset time::80Sublingual onset time units::minutes, Come up;, Peak;Sublingual min peak time::1.5 - Sublingual max peak time::2Sublingual peak time units::hours, Offset;, After effects;Sublingual min afterglow time::1 - Sublingual max afterglow time::3Sublingual afterglow time units::days }} {{#arraydefine: BuccalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: BuccalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: InsufflatedDosage | Threshold;< Insufflated threshold dose::0.2Insufflated dose units::mg, Light;Insufflated min light dose::0.2 - Insufflated max light dose::0.4 mg, Common;Insufflated min common dose::0.4 - Insufflated max common dose::0.8 mg, Strong;Insufflated min strong dose::0.8 - Insufflated max strong dose::1.5 mg, Heavy;Insufflated heavy dose::1.5 mg + }} {{#arraydefine: InsufflatedDuration | Total;Insufflated min total time::8 - Insufflated max total time::14Insufflated total time units::hours, Onset;Insufflated min onset time::30 - Insufflated max onset time::60Insufflated onset time units::minutes, Come up;, Peak;Insufflated min peak time::4 - Insufflated max peak time::8Insufflated peak time units::hours, Offset;, After effects;Insufflated min afterglow time::1 - Insufflated max afterglow time::3Insufflated afterglow time units::days }} {{#arraydefine: RectalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: RectalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: TransdermalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: TransdermalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SubcutaneousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SubcutaneousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntramuscularDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntramuscularDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntravenousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntravenousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: uncertaininteractions | {{#ask:SubstanceBox/Buprenorphine |?UncertainInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: unsafeinteractions | {{#ask:SubstanceBox/Buprenorphine |?UnsafeInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: dangerousinteractions | {{#ask:SubstanceBox/Buprenorphine |?DangerousInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arrayprint:uncertaininteractions||@@@@| }} {{#arrayprint:unsafeinteractions||@@@@| }} {{#arrayprint:dangerousinteractions||@@@@| }}
SubstanceBox/Buprenorphine
Chemical Nomenclature
Common names common name::Buprenex, common name::Subutex, common name::Butrans, common name::Cizdol, common name::Addnok, common name::Transtec
Systematic name (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
Class Membership
Psychoactive class psychoactive class::Opioid
Chemical class chemical class::Morphinan
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





{{#arrayunique: SublingualDosage}} {{#loop: i | 0 | {{#arraysize: SublingualDosage}} | {{#arraydefine: val | {{#arrayindex: SublingualDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: SublingualDuration}} {{#loop: i | 0 | {{#arraysize: SublingualDuration}} | {{#arraydefine: val | {{#arrayindex: SublingualDuration | {{#var: i}} }} | ; }} }}
⇣ Sublingual
Dosage
Bioavailability 30%[1]
[[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
Duration
[[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
{{#arrayunique: InsufflatedDosage}} {{#loop: i | 0 | {{#arraysize: InsufflatedDosage}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: InsufflatedDuration}} {{#loop: i | 0 | {{#arraysize: InsufflatedDuration}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDuration | {{#var: i}} }} | ; }} }}
⇣ Insufflated
Dosage
Bioavailability 48%[2]
[[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
Duration
[[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
@@@@
@@@@
@@@@
  1. ↑ Mendelson, J., Upton, R. A., Everhart, E. T., Jacob, P., Jones, R. T. (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–37. doi:10.1177/009127009703700106. ISSN 0091-2700. 
  2. ↑ Eriksen, J., Jensen, N. H., Kamp-Jensen, M., Bjarnø, H., Friis, P., Brewster, D. (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–805. doi:10.1111/j.2042-7158.1989.tb06374.x. ISSN 0022-3573.